1-chloro-5-aminopentane hydrochloride | 1745-60-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: 1-chloro-5-aminopentane hydrochloride
• 英文别名: 5-chloropentane-1-amine hydrochloride；5-chloropentanamine hydrochloride；5-chloropentan-1-amine hydrochloride；5-chloro-pentylamine; hydrochloride；5-Chlor-pentylamin; Hydrochlorid；5-Chloropentylamine hydrochloride；5-chloropentan-1-amine;hydrochloride
• CAS: 1745-60-4
• 化学式: C₅H₁₂ClN*ClH
• 分子量: 158.071
• InChiKey: MXMGNWPTOBCQIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-chloro-5-aminopentane hydrochloride 在 水 作用下， 生成 5-氨基-1-戊醇
  参考文献：
  名称：

  Production of aminoalkyl sulfonic acids and aminoalkanols

  摘要：

  公开号：

  US02851484A1
• 作为产物：
  描述：

  5-chloro-1-azidopentane 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以75%的产率得到1-chloro-5-aminopentane hydrochloride
  参考文献：
  名称：

  Aliphatic amino azides as key building blocks for efficient polyamine syntheses

  摘要：

  New routes to open-chain polyamines have been developed using aliphatic amino azides as common precursors for the construction of the carbon-nitrogen framework. These alpha,omega-diaminoalkane synthetic equivalents were combined with (omega-halogenoalkyl)dichloroboranes to extend the polyamine chain from the azido moiety. An extension from the free amino group can also be achieved via a Michael type addition with acrylonitrile or a reductive amination with a gamma-azido ketone. Further transformations led to a large variety of regioselectively C- or (and) N-substituted polyamines.

  DOI：

  10.1021/jo00066a028

文献信息

• MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：US20180221279A1

  公开（公告）日：2018-08-09

  Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

  本文提供了适用于装载到脂质体纳米粒载体中的药物衍生物。在一些首选方面，这些衍生物包括一种水溶性较差的药物衍生物，其与一种弱碱基团衍生化，有助于通过LN跨膜pH或离子梯度将药物活性地装载到LN的水相内部。弱碱基团可以选择性地包括一个亲脂性结构域，有助于将药物活性地装载到脂质体膜的内单分子层。优点是，药物衍生物的LN配方相对于相应的游离药物表现出改善的溶解度、降低的毒性、增强的疗效和/或其他优点。
• Remote Site-Specific Radical Alkynylation of Unactivated C–H Bonds
  作者：Lin Wang、Yong Xia、Klaus Bergander、Armido Studer

  DOI：10.1021/acs.orglett.8b02514

  日期：2018.9.21

  A method for remote radical C–H alkynylation at unactivated sites is reported. C–H functionalization proceeds via 1,5-hydrogen atom transfer (HAT) to amidyl radicals that are generated via an addition/fragmentation reaction. The readily installed N-allylsulfonyl moiety is used as a precursor of the N-centered radical. Unactivated secondary and tertiary as well as selected primary C–H bonds can be functionalized

  报道了一种在未激活位点进行远程自由基C–H炔基化的方法。C–H官能化通过1,5-氢原子转移（HAT）进行，通过加成/片段化反应生成的a基自由基。易于安装的N-烯丙基磺酰基部分用作N中心自由基的前体。未激活的二级和三级以及选定的一级C–H键可通过此方法进行功能化。
• Synergetic Effect of Monomer Functional Group Coordination in Catalytic Insertion Polymerization
  作者：Hannes Leicht、Inigo Göttker-Schnetmann、Stefan Mecking

  DOI：10.1021/jacs.7b03087

  日期：2017.5.24

  PhNH-functionalized dienes are copolymerized efficiently with butadiene to stereoregular copolymers by [(mesitylene)Ni(allyl)][BArF4] (Ni-1). Overall polymerization rates and comonomer incorporations depend strongly on the linker length between the diene moiety and functional group, in, e.g., PhS-(CH2)xC(═CH2)-CH═CH2 (PhS-x-BD, x = 3-7), in particular for certain linker lengths high comonomer reactivity ratios stand

  PhS-和PhNH-官能化的二烯通过[(均三甲苯)Ni(烯丙基)][BArF4] (Ni-1)与丁二烯有效共聚成有规立构共聚物。总聚合速率和共聚单体掺入强烈依赖于二烯部分和官能团之间的接头长度，例如，PhS-(CH2)xC(=CH2)-CH=CH2 (PhS-x-BD，x = 3-7 )，特别是对于某些接头长度，高共聚单体反应性比突出。这种效应与共聚单体与活性位点的有利结合有关，包括其官能团的配位，这显着增强了共聚单体在增长的聚合物链中的结合。
• Isoindoles having cardiovascular activity
  申请人：Italfarmaco S.p.A.

  公开号：US05376673A1

  公开（公告）日：1994-12-27

  Isoindole compounds of the formula (I) ##STR1## wherein R.sub.1 represents hydrogen; C.sub.1 -C.sub.6 alkyl; benzyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, methylenedioxy; C.sub.2 -C.sub.8 aliphatic acyl; benzoyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyl, C.sub.2 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, methylenedioxy; R.sub.2 -R.sub.3 are selected independently from hydrogen; halogen; C.sub.1 -C.sub.4 alkyl; trifluoromethyl; hydroxy; nitro; amino; mono or di C.sub.1 -C.sub.4 alkylamino; cyano; C.sub.1 -C.sub.6 alkoxy; C.sub.2 -C.sub.6 alkoxycarbonyl; Y is ethylene, or a straight or branched alkylene chain containing from 3 to 6 carbon atoms, and the salts thereof of pharmaceutically acceptable acids. The compounds possess antianginal activity and are used in the preparation of medicaments for antianginal therapy.

  式(I)的异吲哚化合物 ##STR1## 其中R.sub.1代表氢; C.sub.1-C.sub.6烷基; 可选用卤素，羟基，C.sub.1-C.sub.6烷氧基，亚甲二氧基取代的苯甲基; C.sub.2-C.sub.8脂肪酰基; 可选用卤素，羟基，C.sub.1-C.sub.6烷氧基，C.sub.2-C.sub.6烷酰基，C.sub.2-C.sub.6烷酰氧基，C.sub.1-C.sub.4烷基，三氟甲基，亚甲二氧基取代的苯甲酰基; R.sub.2-R.sub.3独立选择自氢; 卤素; C.sub.1-C.sub.4烷基; 三氟甲基; 羟基; 硝基; 氨基; 单或双C.sub.1-C.sub.4烷基氨基; 氰基; C.sub.1-C.sub.6烷氧基; C.sub.2-C.sub.6烷氧羰基; Y为乙烯或含有3至6个碳原子的直链或支链烷基链，以及其在药学上可接受的酸盐。这些化合物具有抗心绞痛活性，并用于制备抗心绞痛治疗药物。
• [EN] TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM<br/>[FR] TRIAZINANES POSSÉDANT DES GROUPES À EXTRÉMITÉ THIOSULFONATE ET LEURS PROCÉDÉS DE FABRICATION
  申请人：FLEXSYS AMERICA LP

  公开号：WO2021216487A1

  公开（公告）日：2021-10-28

  The present invention is directed to compounds represented by the formula (I): wherein R1 comprises a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. wherein R2 comprises an alkylene group, an arylene group, or a heterocyclic group. The three R2 groups may be the same or different. wherein A comprises an alkyl, an aryl, or an alkylaryl group. The three A groups may be the same or different.39

  本发明涉及由以下式（I）表示的化合物：其中R1包括一个氢原子或具有1至2个碳原子的烷基基团。其中R2包括一个烷基基团、芳基基团或杂环基团。三个R2基团可以相同也可以不同。其中A包括一个烷基、芳基或烷基芳基基团。三个A基团可以相同也可以不同。